Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Fig. 1

Change in WOMAC Pain, WOMAC Physical Function, and PGA-OA. LS mean (SE) changes, from baseline, in WOMAC Pain (A), WOMAC Physical Function (B), and PGA-OA (C) scores are shown over the 56-week treatment period. *Unadjusted p ≤ 0.05 for tanezumab 2.5mg versus NSAID. +Unadjusted p ≤ 0.05 for tanezumab 5mg versus NSAID. LS, least squares; NSAID, nonsteroidal anti-inflammatory drug; PGA-OA, Patient’s Global Assessment of Osteoarthritis; SE, standard error; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us